Skip to main content
Figure 7 | BMC Cancer

Figure 7

From: The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40

Figure 7

T cell proportions and activation in the tumor following combined debulking surgery with IMQ and/or anti-CD40. BALB/c mice bearing AB1-HA tumors underwent debulking surgery and treatment with IMQ (50 μg i.t. q1dx6 on day of surgery) and/or anti-CD40 (100 μg i.p. q1dx1, starting one day after surgery). On day 26, the tumors were removed for analysis of T cell subsets by flow cytometry. CD4+ and CD8+ T cells were identified as% of total lymphocytes (based on forward and side scatter), and analysed for ICOS expression (activation status) as% of total CD4+ or CD8+ T cells. *p < 0.05, **p < 0.01, ***p < 0.001 compared to untreated; Kruskal-Wallis test with Dunn’s correction for multiple comparisons.

Back to article page